Codexis

CDXSPhase 1

Redwood City, United StatesFounded 2002codexis.com

Founded in 2002, Codexis has pioneered the use of engineered enzymes for pharmaceutical manufacturing, with a proven track record including the scale-up of an enzyme for Pfizer's Paxlovid. The company has strategically expanded into RNA manufacturing, offering a full enzymatic synthesis platform for oligonucleotides like siRNA. Codexis operates as a partner-driven business, providing custom enzyme solutions and manufacturing services to accelerate and de-risk therapeutic development for its clients.

Market Cap

$1.8B

Founded

2002

CDXS · Stock Price

USD 20.00+9.40 (+88.68%)

Historical price data

AI Company Overview

Technology Platform

Codexis leverages two core platforms: CodeEvolver®, an AI/ML-driven enzyme engineering platform for creating optimized biocatalysts, and ECO Synthesis®, an enzymatic manufacturing platform for the scalable, sustainable production of RNA therapeutics like siRNA.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
CDX-6114 + Placebo	Healthy	Phase 1
CDX-6114 + Placebo	Healthy	Phase 1

Funding History

Total raised: $187M

IPO$78MUndisclosedApr 22, 2010

Series C$40MMaxygenJun 15, 2007

Series B$45MMaxygenJun 15, 2005

Series A$24MMaxygenJun 15, 2002

Opportunities

The rapid growth of the RNA therapeutics market creates a massive demand for scalable, cost-effective manufacturing, which Codexis's ECO Synthesis® platform is designed to address.

Additionally, the global push for greener pharmaceutical production aligns perfectly with the sustainability benefits of enzymatic biocatalysis, opening doors across both small molecule and oligonucleotide manufacturing.

Risk Factors

Codexis's success is highly dependent on convincing risk-averse pharmaceutical partners to adopt its novel enzymatic manufacturing processes over established chemical methods.

The company also faces competition from large CMOs and internal pharma capabilities, and its revenue stream is tied to the success and timing of its partners' drug development programs.

Competitive Landscape

Codexis competes with traditional chemical synthesis CMOs (e.g., Lonza, Catalent) and specialist oligonucleotide manufacturers, differentiating through its proprietary enzymatic technology. In biocatalysis, it faces firms like Arzeda and Novozymes. Its key advantages are a proven commercial track record (Januvia®, Paxlovid), deep enzymology expertise, and its integrated AI-driven engineering platform.